Portal vein infusion chemotherapy with gemcitabine after surgery for pancreatic cancer
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Pancreatic cancer still has a poor prognosis even after curative resection because of the high incidence of postoperative liver metastasis. This study prospectively evaluated the feasibility and tolerability of portal vein infusion chemotherapy of gemcitabine (PVIG) as an adjuvant setting after pancreatic resection.
Thirteen patients enrolled in this study received postoperative chemotherapy with PVIG. The patients received intermittent administration of gemcitabine (800 mg/m2) via the portal vein on days 1, 8, and 15 after surgery. The tolerability and the toxicity of PVIG were closely monitored.
The PVIG was started on an average of 3.1 days after surgery. Complete doses of chemotherapy (three sessions of portal infusion) were accomplished in 11 of the 13 patients. Grade 3 or 4 leukocytopenia was observed in three patients (23 %), and liver dysfunction was found in one patient (7.7 %). Grade 2 sepsis developed in two cases due to bloodstream infection. Liver metastasis was the first site of recurrence in only two patients.
PVIG can be administered to the liver with acceptable toxicity, but myelosuppression is similar to the systemic use of gemcitabine. Careful observation is required even for locoregional chemotherapy.
- Amikura K, Kobari M, Matsuno S. The time of occurrence of liver metastasis in carcinoma of the pancreas. Int J Pancreatol. 1995;17:139–246.
- Ishikawa O, Ohigashi H, Sasaki Y, Furukawa H, Kabuto T, Kameyama M, et al. Liver perfusion chemotherapy via both the hepatic artery and portal vein to prevent hepatic metastasis after extended pancreatectomy for adenocarcinoma of the pancreas. Am J Surg. 1994;168:361–4. CrossRef
- Ishikawa O, Ohhigashi H, Sasaki Y, Furukawa H, Imaoka S. Extended pancreatectomy and liver perfusion chemotherapy for resectable adenocarcinoma of the pancreas. Digestion. 1999;60(Suppl 1):135–8. CrossRef
- Kurosaki I, Kawachi Y, Nihei K, Tsuchiya Y, Aono T, Yokoyama N, et al. Liver perfusion chemotherapy with 5-fluorouracil followed by systemic gemcitabine administration for resected pancreatic cancer: preliminary results of a prospective phase 2 study. Pancreas. 2009;38:161–7. CrossRef
- Takahashi S, Ogata Y, Miyazaki H, Maeda D, Murai S, Yamataka K, et al. Aggressive surgery for pancreatic duct cell cancer: feasibility, validity, limitations. World J Surg. 1995;19:653–9. CrossRef
- Nakayama S, Takeda S, Kawase Y, Inoue S, Kaneko T, Nakao A. Clinical significance of dihydropyrimidine dehydrogenase in adjuvant 5-fluorouracil liver perfusion chemotherapy for pancreatic cancer. Ann Surg. 2004;240:840–4. CrossRef
- Ohigashi H, Ishikawa O, Eguchi H, Sasaki Y, Yamada T, Noura S, et al. Feasibility and efficacy of combination therapy with preoperative and postoperative chemoradiation, extended pancreatectomy, and postoperative liver perfusion chemotherapy for locally advanced cancers of the pancreatic head. Ann Surg Oncol. 2005;12:629–36. CrossRef
- Ohigashi H, Ishikawa O, Eguchi H, Takahashi H, Gotoh K, Yamada T, et al. Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer. Ann Surg. 2009;250:88–95. CrossRef
- Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs. observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267–77. CrossRef
- Ueno H, Kosuge T, Matsuyama Y, Yamamoto J, Nakao A, Egawa S, et al. A randomized phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer. 2009;101:908–15. CrossRef
- Onoue M, Terada T, Okuda M, Fujimoto K, Doi R, Imamura M, et al. Surgical resection deteriorates gemcitabine-induced leucopenia in pancreatic cancer. Int J Clin Oncol. 2004;9:174–8. CrossRef
- Portal vein infusion chemotherapy with gemcitabine after surgery for pancreatic cancer
Volume 43, Issue 1 , pp 33-39
- Cover Date
- Print ISSN
- Online ISSN
- Springer Japan
- Additional Links
- Portal vein infusion chemotherapy
- Adjuvant chemotherapy
- Pancreatic cancer
- Liver metastasis
- Industry Sectors
- Author Affiliations
- 1. Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-dori, Niigata, 951-8510, Japan
- 2. Department of Surgery, Nagaoka Chuo General Hospital, Nagaoka, Japan
- 3. Department of Surgery, Tsuruoka Municipal Shonai Hospital, Tsuruoka, Japan
- 4. Department of Surgery, Niigata Cancer Center Niigata Hospital, Niigata, Japan